Angel City's Savy King has heart surgery following on-field collapse
Angel City defender Savy King was recovering from heart surgery following her collapse on the field during a National Women's Soccer League match on Friday night.
Article content
King was taken to Cedars-Sinai Medical Center in Los Angeles following the medical event in the second half of Angel City's match against the Utah Royals. Doctors who evaluated King discovered a heart abnormality, and she underwent surgery Tuesday.
Article content
'She is now resting and recovering surrounded by her family, and her prognosis is excellent,' the team said in a statement.
Article content
King's family released a joint statement thanking the team's medical staff, King's fellow players and the hospital medical staff for her care.
Article content
'On behalf of our entire family, along with Savy, we have been so moved by the love and support from Angel City players, staff, fans and community, as well as soccer fans across the country,' the statement said. 'We are blessed to share Savy is recovering well and we are looking forward to having her home with us soon.'
Article content
Players on both sides were visibly shaken as trainers rushed to King's side after she went down in the 74th minute of Friday's match. She was attended to for some 10 minutes before she was stretchered off the field on a cart.
Article content
Angel City said King was transported to the hospital but was responsive and undergoing further evaluation.
Article content
'We are grateful to the Angel City medical staff as well as to local paramedics who handled this difficult situation seamlessly,' the NWSL said in a statement on Saturday.
Article content
In an Instagram story, Washington Spirit national team forward Trinity Rodman offered prayers for King and her family, adding: 'In no world should that game have continued.'
Article content
The league said in its statement that it would review its policies to determine if changes needed to be made.
Article content
NWSL rules for 2025 state that the league 'recognizes that emergencies may arise which make the start or progression of a Game inadvisable or dangerous for participants and spectators. Certain event categories automatically trigger the League Office into an evaluation of whether delay or postponement is necessary.'
Article content
There were 12 minutes of stoppage time added to the match. Angel City won the game 2-0.
Article content
King, 20, was the second overall pick in the 2024 NWSL draft by expansion Bay FC and played 18 games for the club. She was traded to Angel City in February and had started in all eight games for the team this season.
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
21 minutes ago
- Globe and Mail
Dr. Louis Krenn Scholarship for Medical Students Invites Future Physicians to Share Their Vision for the Future of Medicine
The Dr. Louis Krenn Scholarship for Medical Students is officially open for applications, offering undergraduate and medical students across the United States a meaningful opportunity to reflect on their journey into healthcare and articulate their aspirations for shaping its future. Springfield, Missouri - The Dr. Louis Krenn Scholarship for Medical Students is officially open for applications, offering undergraduate and medical students across the United States a meaningful opportunity to reflect on their journey into healthcare and articulate their aspirations for shaping its future. This scholarship initiative, personally established by Dr. Louis Krenn, aims to recognize students who demonstrate a deep sense of purpose and commitment to a career in medicine. This scholarship is not limited by geographic boundaries and welcomes submissions from eligible applicants throughout the United States. With a one-time award of $1,000, the Dr. Louis Krenn Scholarship for Medical Students supports future doctors in their academic and professional pursuits, offering not only financial assistance but also recognition of their dedication to service, innovation, and compassion. To qualify, applicants must be currently enrolled as undergraduate or medical students within the United States and must be actively pursuing a pre-med or medical school track. Each applicant is required to submit a personal essay addressing the following prompt: ' Medicine is more than a career—it's a calling. What inspired you to pursue a path in healthcare, and how do you hope to shape the future of medicine through your work? ' Essays must range between 500 and 800 words. Submissions will be evaluated based on originality, insight, and alignment with the core values that have guided Dr. Louis Krenn's career: service to others, innovative thinking, and compassionate care. Dr. Louis Krenn is a respected Family Medicine physician with more than two decades of clinical practice and leadership experience. Based in Springfield, Missouri, Dr. Louis Krenn has held key roles in clinical efficiency, telehealth expansion, and medical education. His impact at CoxHealth and his mentorship of emerging healthcare professionals reflect a lifelong dedication to improving patient care and shaping the future of medicine. Over the years, Dr. Louis Krenn has not only practiced medicine but also led transformative projects in healthcare delivery. His efforts in clinical process improvement and his advocacy for telemedicine have set a forward-looking example for aspiring doctors. Through this scholarship, Dr. Louis Krenn continues his commitment to mentoring the next generation of healthcare professionals. Applicants are encouraged to visit the official scholarship website to review eligibility and submission requirements: The deadline for submission is March 15, 2026, and the winning applicant will be announced on April 15, 2026. By inviting students to reflect on their motivations and long-term goals, the Dr. Louis Krenn Scholarship for Medical Students serves as a platform to elevate voices that are shaping the next era of healthcare. With a clear focus on values that matter most in medicine, this scholarship honors the journey of becoming a physician and recognizes the essential human connection that underpins the practice. The scholarship also underscores a broader vision: to encourage thoughtful leadership in medicine. Dr. Louis Krenn believes that by supporting students at the earliest stages of their careers, the field of medicine will continue to evolve with greater empathy, ingenuity, and resilience. This annual initiative is one of many ways Dr. Louis Krenn remains committed to nurturing future leaders in medicine. It reflects his deep belief that the future of healthcare depends not only on science and technology, but also on the strength of those who choose to serve through medicine. About Dr. Louis Krenn Dr. Louis Krenn earned his medical degree from the University of Arkansas for Medical Sciences and completed his Family Medicine residency at Cox Family Medicine Residency Program. He has served in numerous leadership positions at CoxHealth and continues to be actively involved in clinical practice and medical education. His work stands as a testament to his belief in excellence, compassion, and continuous growth within the healthcare profession. Media Contact Company Name: Dr. Louis Krenn Scholarship Contact Person: Dr. Louis Krenn Email: Send Email City: Springfield State: Missouri Country: United States Website:
CTV News
an hour ago
- CTV News
Despite Kennedy's claims, vaccines have been tested in placebo-controlled studies
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly claimed that most vaccines recommended for children in the U.S. have not been tested against inert placebos. (Demetrius Freeman/Thevia CNN Newsource) U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has repeatedly claimed in public statements that most vaccines recommended for children in the U.S. have not been tested against placebos, and particularly inert placebos such as saline solution or water. 'The only vaccine that has been tested in a full-blown placebo trial against an inert placebo was the Covid vaccine,' Kennedy said May 14 in testimony before the U.S. Senate's Health, Labor, Education and Pensions Committee. 'The other 76 shots that children in this country received between birth and 18 years old, none of them have been safety tested in prelicensing studies against the placebo, which means we don't understand the risk profile for those products, and that's something I intend to remedy,' he told Sen. Chris Murphy, D-Connecticut. In 2023, Kennedy told Fox News host Jesse Watters: 'Vaccines are exempt from prelicensing placebo-controlled trials, so that there's no way that anybody can tell the risk profile of those products or even the relative benefits of those products before they're mandated. And we should have that kind of testing.' HHS is acting on Kennedy's claims, too. The department recently announced it will require all new vaccines be tested in placebo-controlled trials before they're licensed for use, a change it called 'a radical departure from past practices.' These claims made Dr. Jake Scott's ears perk up. Scott, an infectious disease specialist at Stanford University, knew that the assertions couldn't be true, and now he says he has the proof. Scott launched a project in April to round up every randomized and placebo-controlled clinical trial of vaccines in the medical literature, including studies run in other countries, since some vaccines used in the U.S. are tested overseas. It took five weeks to arrive at a number: There have been 258 randomized, controlled clinical trials of vaccines, according to Scott and a team of volunteers who scoured databases of medical literature. More than half of those studies — 153 — tested vaccines against placebos, and 127 of those studies used inert placebos. A randomized, controlled trial may use another vaccine. For their dataset, Scott said they considered a trial placebo-controlled only if the placebo didn't contain an antigen — the active vaccine ingredient. Based on Scott's research, at least nine of the 16 vaccines that are routinely recommended by the U.S. Centers for Disease Control and Prevention for children have been tested against inert placebos, while several more have been tested against active controls, such as another type of vaccine. In scientific research, randomized, placebo-controlled clinical trials are considered to generate the highest-quality evidence. That's because they split their study participants into equal groups; some get the study intervention or treatment, while others get a placebo or dummy remedy. Placebos are often carefully designed to look, taste or even smell like the intervention that's being tested. The idea is to keep both the participants and the researchers themselves in the dark about who's getting the real thing until the end of the study, when the results are analyzed and reported, to prevent any potential bias. HHS did not respond to CNN's request for comment on the new project's findings or clarification on Kennedy's statements. Crowdsourcing vaccine research On April 22, Scott posted a link to a shared Google spreadsheet online, along with some ground rules about which trials could and couldn't be included. The studies had to be in humans; no animal studies or lab-only investigations allowed. The researchers also used a particular set of search terms, with no limits on dates, languages or pathogens. The team then read each study that was found to make sure it met the specified criteria for inclusion in the review. 'It took off,' Scott said. He estimates that the project had five or six core contributors, but they had help from around the world. Together, they scoured PubMed, the database of medical research maintained by the National Library of Medicine, as well as reference lists from Cochrane, the World Health Organization and the CDC. Dr. Isaac Bogoch, an infectious disease specialist at the University of Toronto, said he was blown away when he saw the final list of studies, which included about 2.5 million participants in total. 'The body of evidence for many of the vaccines that we use is very impressive, and the data is robust,' said Bogoch, who didn't contribute to the project. 'This type of work is extremely important in era of unprecedented vaccine hesitancy.' A 'demonstrably false' claim Scott said the research proves that Kennedy's statements are 'demonstrably false.' To understand why, it's useful to break down the parts of Kennedy's argument, which he has repeated in different iterations for years. Kennedy has shifted the goalposts, but there are a few things he has said would make a clinical trial meet his requirements: First, an inert placebo, meaning a placebo control that didn't have any biological effects on the body, like water or saline solution. Kennedy has said that without comparison to an inert placebo, the true side effects of vaccines can't be fully understood. He also uses the term 'prelicensing,' meaning the research is conducted before the U.S. Food and Drug Administration has approved the vaccines. The FDA sometimes accepts enough evidence to approve a vaccine but then will require more safety studies and monitoring after approval. Kennedy and other critics argue that more safety testing should be done before the vaccines are approved in the first place. In some instances, Kennedy has also said that these studies should be large, including many participants, and long-running. In general, larger studies have greater statistical power to show subtle differences between groups. And the longer a trial follows its participants, the more confident researchers can be in the durability of their results. Although scientists agree that larger and longer clinical trials are the most reliable, these studies are expensive to conduct. They can take years to run, which delays the possibility of getting an effective intervention to people. It can also be difficult to find participants who can stick with the monitoring requirements of a study for longer periods of time. In recent testimony, however, even Kennedy seemed to be softening his stance on this particular stipulation, agreeing that other types of studies can provide solid evidence, too. 'You know that the Cochrane Collaboration in 2016 published a study that showed that the predictive capacity of placebo-controlled trials, which are the gold standard, is actually not any better than good observational trials in retrospective trials. So we can do those kind of studies without subjecting people to an unethical experiment,' Kennedy said during a May 20 Senate budget hearing when asked about the need to test established vaccines in large, lengthy placebo-controlled trials. In his 2021 book, 'The Real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health,' Kennedy repeats the claim that vaccines for children haven't been tested against inert placebos, saying that he and groups he's affiliated with have explicitly asked to be shown such studies. He cites two letters between the Informed Consent Action Network or ICAN, a group run by his close associate Del Bigtree, and HHS. The letter from ICAN asserts that in contrast to most other FDA-approved medications, 'vaccines are not required to undergo long-term double-blind inert-placebo controlled trials to assess safety. In fact, not a single one of the clinical trials for vaccines given to babies and toddlers had a control group receiving an inert placebo.' The HHS letter refutes this claim: 'Contrary to statements made on page two of your letter, many pediatric vaccines have been investigated in clinical trials that included a placebo.' The letter goes on to say inert placebos are not necessary to understand the safety of a new vaccine, and so they haven't been required. Still, Scott says the evidence is clear: Of the 258 randomized, controlled vaccine studies he and his colleagues found, about half – 127 – included inert placebos. When it comes to vaccines routinely recommended for children, specifically, Scott found that at least nine of the 16 on the CDC's regular schedule have been tested against inert placebos: These are the vaccines against Covid-19; rotavirus; polio; influenza; measles, mumps and rubella; human papillomavirus; varicella, or chickenpox; pneumococcal; and H-flu, or Haemophilus influenzae. One of the largest of these trials was on the polio vaccine. The placebo-controlled part of the study included more than 400,000 grade-schoolers. Half got the inactivated polio vaccine created by Dr. Jonas Salk, and the other half were given injections of an inert placebo, which was saline solution. The trial was conducted in 1954, and the results were announced in April 1955. So great was the urgency to get the vaccine to kids that the FDA licensed it the same day. 'It's frankly astounding that someone who made such easily disprovable claims is now heading HHS and continues to promote similar misinformation,' Scott said of Kennedy in an email to CNN. 'We compiled this evidence specifically to counter these false narratives with hard data.' Scott says he and his colleagues hope to have their project published in peer-reviewed medical journal soon. For now, it's available in a publicly posted spreadsheet. Vaccines In scientific research, randomized, placebo-controlled clinical trials are considered to generate the highest-quality evidence. (via CNN Newsource_ Active controls vs. inert placebos Vaccine trials that don't use inert placebos will sometimes use what are known as active controls. These comparison shots have some biological effect but don't interfere with scientists' ability to interpret the results of their study. Active controls are used for a variety of reasons. In some parts of the world, for example, where it might be difficult to recruit participants, researchers might give the control group an unrelated vaccine to make sure they're getting some benefit by enrolling in the study. One study published last year in the Lancet, testing a vaccine against malaria, gave participants in the control group a vaccine against rabies instead. Rabies vaccines don't protect against malaria, so they wouldn't interfere with researchers' ability to tell whether the malaria shot actually worked. Other types of controls in the studies in Scott's project included shots that contained only an adjuvant, an ingredient that's added to vaccines to trigger a stronger immune response. Dr. Greg Poland, who studies how adults and children respond to vaccines at the Mayo Clinic, said it would be a mistake to assume that active controls can't be valid and rigorous ways to test vaccines. Adjuvants, such as aluminum, are often the reason people get soreness around an injection site. Giving just the adjuvant can guard against even psychological bias in control participants who might guess that they didn't get a real vaccine if they didn't feel anything after their shots. It also allows researchers to isolate the benefits and side effects of the vaccine, since everyone got the adjuvant. 'You're literally saying, 'OK, we're testing a vaccine that has ingredient A plus B against a non-vaccine placebo that has ingredient B.' So the only thing different between the two of them is the actual vaccine,' Poland said. An active comparator might also be used rather than an inert placebo because of ethics. When there's already a vaccine that's considered to be safe and effective against an infection, it's considered unethical to deny study participants the chance to get it. In that case, companies that want to test a new and improved version of a vaccine against an older one would normally have to offer participants in their control group the older vaccine. Many modern vaccines have been compared against older versions of the same vaccine. Flu vaccines are a good example, Poland says. If you were testing an improved type of flu vaccine, chances are that the board that oversees your clinical trial wouldn't approve a study that used an inert placebo – especially if you were testing it in a vulnerable group, like people over 65, for whom an infection is more likely to be dangerous. 'It's unethical because the recommendation is that everyone, each flu season, receive an influenza vaccine. So it'd be unethical to enroll people in a study where they may just get placebo and not get any benefit of protection,' Poland said. Poland said he's been puzzled by Kennedy's statements, too. He's concerned that they are getting traction with the public now that Kennedy is the head of the nation's health agencies. 'This notion that there are no placebo-controlled vaccine trials is patently false, but it's a really interesting phenomenon that I have a hard time understanding,' he said. Article by Brenda Goodman.
CBC
2 hours ago
- CBC
Doctors Manitoba cheers changes to help U.S. physicians relocate to province
Regulatory changes intended to make it easier for U.S.-based physicians to relocate and practice in Manitoba are being loudly applauded by an advocacy group in the province. "We're really excited about it. Manitoba has one of the worst doctor shortages in the country, and as practising physicians, we see the consequences of this every day," said Doctors Manitoba president Nichelle Desilets. The College of Physicians and Surgeons of Manitoba and the provincial government recently took steps to streamline the process for qualified physicians from the United States to be granted a full licence to practice in the province, provided they meet certain requirements. They have to first complete an accredited residency program, have certification from the American Board of Medical Specialists and have a licence from a U.S. state medical board. "The training that American physicians undergo is very similar to a Canadian physician. I would even say nearly identical," said Desilets, who practises in Neepawa. "There is much more in common than there is different." Processes the government and college have agreed to remove include things like requiring supervisors and formal assessments, and restrictions on where a new doctor can practise — which can all be costly and time-consuming. Doctors Manitoba advocated for such changes more than a year ago, Desilets said. "Manitoba has been behind in making these changes, so it's really great to see that we're catching up on that," Desilets said. B.C., Saskatchewan, New Brunswick, Nova Scotia and P.E.I. have already simplified the process, she said. It's also important to underscore the fact that none of the changes will compromise the quality of patient care, she said. "The public should still be reassured that there is still a rigorous process making sure that every doctor that practises in Manitoba is qualified to do so and has been vetted by our college." The province has also followed the lead of Doctors Manitoba by launching recruitment campaigns in the U.S. The provincial government is targeting health-care workers in the nearby states of Michigan, Minnesota, North Dakota and South Dakota, touting Manitoba's strengths and priorities, including safe and inclusive communities, good schools, strong social supports and comparable affordability with a high quality of life. Doctors Manitoba had ramped up its own recruitment efforts late last year with a similar message in an effort to appeal to physicians in search of stability and respect after Donald Trump was elected U.S. president. "We have the privilege of working in an environment where the government doesn't generally get in between us and our patients, so that was the kind of the selling point that we brought," Desilets said. "We're grateful to see that our public advocacy efforts were able to influence government stakeholders and our own regulatory college to take a look at all of the requirements and to kind of take our lead." She couldn't say, though, if the efforts have prompted anyone to relocate north of the border. "As a front-line working doctor, I wouldn't be privy to that knowledge, but we do know that our office has had people reach out to inquire about the process and what the work environment looks like," Desilets said. "Despite the flaws in our health-care system, and I acknowledge that there are many of them, I am safe when I go to work, I know that the government is going to pay me for the services that I provide to patients, and I know that I have an organization that backs me and my colleagues up when we go to work every day." Doctors Manitoba will continue to promote those benefits through its own recruitment efforts in news media interviews, advertisements, and the website ManitobaMD.com. While the push to open the door more to American doctors is welcome, it's only one aspect of addressing the shortage, Desilets said. The barriers between provinces need to be dealt with, as well. "Even though people expect health care to be nationally available to them, it's still administered on a provincial level. So this is a barrier to recruiting physicians to Manitoba, no matter where you're coming from," she said. "The fact that we don't have enough doctors to serve our population is a multi-pronged challenge. There's not one golden answer … and we're going to continue to advocate. We need more doctors, we need more specialists."
